Chemoradiotherapy with Concurrent Durvalumab for the Palliative Treatment of Oligometastatic Oesophageal and Gastrooesophageal Carcinoma with Dysphagia: a Single Arm Phase II Clinical Trial (PALEO, Sponsored by the Australasian Gastro-Intestinal Trials Group)
BMC Cancer（2022）
Key words
Oesophageal,Gastro-oesophageal (GOS),Dysphagia,Oligometastatic,Chemoradiotherapy,Checkpoint inhibition,Chemoradioimmunotherapy,PD-1,PD-L1,Durvalumab.
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined